Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study.

Eurich DT, Johnstone JJ, Minhas-Sandhu JK, Marrie TJ, Majumdar SR.

Heart. 2012 Jul;98(14):1072-7. doi: 10.1136/heartjnl-2012-301743.

PMID:
22739637
2.

Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.

Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR.

Clin Infect Dis. 2010 Jul 1;51(1):15-22. doi: 10.1086/653114.

PMID:
20504233
3.

Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up.

Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A, Gomez F, Raga X, de Diego C, Satue E, Salsench E; EPIVAC Study Group.

BMC Public Health. 2012 Mar 22;12:222. doi: 10.1186/1471-2458-12-222.

4.

Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.

Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, de Diego C, Salsench E, Raga X, Fuentes-Bellido CM.

BMC Public Health. 2010 Jan 19;10:25. doi: 10.1186/1471-2458-10-25.

5.

Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.

Johnstone J, Marrie TJ, Eurich DT, Majumdar SR.

Arch Intern Med. 2007 Oct 8;167(18):1938-43.

PMID:
17923592
6.

Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group.

Clin Infect Dis. 2006 Oct 1;43(7):860-8. Epub 2006 Aug 21.

PMID:
16941367
7.

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I.

Clin Infect Dis. 2014 Apr;58(7):909-17. doi: 10.1093/cid/ciu002. Epub 2014 Feb 13.

PMID:
24532544
8.

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.

Koivula I, Stén M, Leinonen M, Mäkelä PH.

Am J Med. 1997 Oct;103(4):281-90.

PMID:
9382120
9.

Effectiveness of pneumococcal polysaccharide vaccine in older adults.

Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink.

N Engl J Med. 2003 May 1;348(18):1747-55.

10.

Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.

Cornu C, Yzèbe D, Léophonte P, Gaillat J, Boissel JP, Cucherat M.

Vaccine. 2001 Sep 14;19(32):4780-90.

PMID:
11535330
11.

Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.

Rodrigo C, Bewick T, Sheppard C, Greenwood S, Macgregor V, Trotter C, Slack M, George R, Lim WS.

Thorax. 2014 Feb;69(2):168-73. doi: 10.1136/thoraxjnl-2013-203987. Epub 2013 Sep 18.

PMID:
24048505
12.

The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients.

Gilbertson DT, Guo H, Arneson TJ, Collins AJ.

Nephrol Dial Transplant. 2011 Sep;26(9):2934-9. doi: 10.1093/ndt/gfq853. Epub 2011 Feb 11.

PMID:
21317410
13.

Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes.

Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, Madjid M, Tweardy D, Musher DM.

Medicine (Baltimore). 2009 May;88(3):154-9. doi: 10.1097/MD.0b013e3181a692f0. Erratum in: Medicine (Baltimore). 2010 May;89(3):195.

14.

Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults.

Hedlund J, Ortqvist A, Konradsen HB, Kalin M.

Scand J Infect Dis. 2000;32(3):281-6.

PMID:
10879599
15.

Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.

Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC.

Clin Infect Dis. 2006 Oct 15;43(8):1004-8. Epub 2006 Sep 1.

PMID:
16983612
16.

Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.

Albrich WC, Baughman W, Schmotzer B, Farley MM.

Clin Infect Dis. 2007 Jun 15;44(12):1569-76. Epub 2007 May 8.

PMID:
17516400
17.
18.

The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the Top End of the Northern Territory, Australia--over 22 years.

Jacups SP, Cheng A.

Vaccine. 2011 Jul 26;29(33):5386-92. doi: 10.1016/j.vaccine.2011.05.082. Epub 2011 Jun 7.

PMID:
21651943
19.

Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.

Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, Sullivan P.

Vaccine. 2008 Oct 29;26(46):5830-4. doi: 10.1016/j.vaccine.2008.08.032. Epub 2008 Sep 9.

PMID:
18786586
20.

Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.

Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K.

Vaccine. 2010 Oct 8;28(43):7063-9. doi: 10.1016/j.vaccine.2010.08.010. Epub 2010 Aug 17.

PMID:
20723631

Supplemental Content

Support Center